

Pfizer Quality Improvement Request for Proposals

Competitive Grant Program – using Pfizer Internal Review Process

Improving Quality of Care and Scalable Implementation of Bispecific Antibody Therapy in Multiple Myeloma

Overview

This competitive grant program supports independent quality improvement (QI) initiatives that seek to improve and standardize the delivery of care for patients with Multiple Myeloma (MM).

The program supports the transition of BCMA-targeting bispecific antibody therapy from specialized centers into routine clinical practice in Germany and aims to enhance health outcomes and quality of life for MM patients treated with bispecific antibodies (BsAbs) through improvements in care coordination, utilization of existing healthcare resources, and optimization of local patient management pathways and healthcare processes.

Geographic Scope

Germany

Project Types and Area of Interest

Potential applicants are encouraged to identify and address relevant needs, barriers, and gaps in the care of MM patients receiving a BCMA-targeting BsAb therapy. Projects should focus on one or more of the following areas:

- *Clinical Process Optimization and Outpatient Care Transformation*
- *Standardize Safety Management and Infection Prevention*
- *Digital and Technology-Enabled Quality Improvement*
- *Multidisciplinary Care Models and Network-Based Approaches*
- *Patient and Caregiver Empowerment*

Key Milestones

Submission Deadline	Anticipated Grant Selection Notification	Anticipated Project Start Date
14 JAN 2027	01 MAR 2027	03 MAY 2027

Funding Range and Project Length

Individual projects requesting up to €100.000 will be considered.
Smaller projects are encouraged (e.g., EUR 30,000–50,000)
Maximum project length is 24 months.

I. Eligibility

Geographic Scope/Location of Project:

- Germany

Applicant Eligibility Criteria:

- **Applicant organizations to this RFP must be based in Germany.**
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/ organizations/ associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead/ Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/ PI's grant/ research coordinator).
- The Project Lead/PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Int. LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Int. LLC may be subject to rescission.

II. Requirements

Primary Area of Interest:

- Oncology - Hematologic - QI

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on:

- Optimization of standardized clinical processes to support the transition from inpatient to outpatient care (including the operationalization of existing step-up dosing models)
- Implementation of structured patient selection approaches to support outpatient eligibility decisions based on existing clinical criteria and risk factors
- Establishment of nurse-led monitoring pathways and automated alert systems to support timely clinical assessment and intervention
- Development of care models that can be replicated across different hospital types and care settings
- Implementation of standardized safety and infection management protocols (e.g. CRS, ICANS, infections) using existing clinical frameworks and routinely available parameters

- Use of existing digital or AI-supported methods for infection or adverse effects risk monitoring, early detection, and alert-based escalation
- Optimization and standardization of monitoring and management approaches based on routinely available clinical and laboratory parameters
- Implementation of existing digital symptom-tracking methods or patient-reported outcome (PRO) solutions soley to support clinical management of patients receiving a BCMA-targeting bispecific antibody therapy (not for research data collection)
- Development of structured remote monitoring pathways to support safe outpatient management
- Establishment of structured collaboration and mentorship models between experienced academic centers and community-based providers
- Development of hub-and-spoke or network-based care models to ensure consistent therapy management across institutions
- Development of structured education programs for patients and caregivers to support symptom recognition and timely escalation
- Development of standardized patient onboarding processes for outpatient and remote monitoring pathways
- Approaches to improve patient self-management during treatment, particularly in the outpatient setting

Out of Scope: It is not our intent to support clinical research projects. The following projects will **not** be considered:

- Projects evaluating the efficacy of therapeutic or diagnostic agents will **not** be considered.
- Projects focused on development of new biomarker technology/techniques will **not** be considered.
- The development of mobile software applications ("Apps") besides implementation of existing ones will **not** be considered.

Target Audience

- The primary audience(s) targeted for this project will be health care professionals (HCPs) focused on Multiple Myeloma (for example hematologists, specialty nurses, pharmacists).

Expected Approximate Monetary Range of Grant Applications

IMPORTANT: Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

- Individual projects requesting **up to €100.000** will be considered. The estimated total available budget related to this RFP is €250.000.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:



IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Click here to navigate to this Competitive Grant Program's unique Program Application Form: Login
  - First-time users should create a Requester Portal account by clicking **Not a member?**
- OR
- Navigate to: https://pfizermarcie.my.site.com/pfzrequester and sign in.
- In the upper navigation bar, click **Grant Programs** to see all available programs.
- Select **Quality Improvement**
- Click **Apply** on the **2026 ONC GER Multiple Myeloma QI** to open the Program Application Form.
- Requirements for submission:
  - Complete all required sections of the online application
  - **IMPORTANT:** Upload proposal (see Appendix) in the Proposal/Protocol field.
- For more information on navigating Pfizer's new grant management system (MARCIE), please refer to this helpful User Guide.

Questions:

- Please click here to view "Frequently Asked Questions" regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Nicola Fenderico or to Global Medical Grants mailbox (nicola.fenderico@pfizer.com or GlobalMedicalGrants@pfizer.com) with the subject line **"2026 ONC GER Multiple Myeloma QI"**

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer International LLC and, if approved the payment will be issued by a Pfizer US based legal entity.

About Pfizer Grants

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

About Pfizer QI Grants

Quality improvement (QI) projects are systematic, data-guided, sustainable activities designed to bring about immediate, positive changes in the delivery of healthcare in particular setting (1,2). Quality improvement seeks to standardize structure and processes to reduce variation, achieve predictable results, and improve outcomes for patients, healthcare systems, and organizations. Structure includes things like technology, culture, leadership, and physical capital. Process includes knowledge capital (e.g., standard operating procedures) or human capital (e.g., education and training) (3).

QI projects systematically apply what is already known into the local practice, intended to quickly improve patient care within a specific setting. The goal of QI projects is to close a gap in performance at a specific health care system. The "performance" is a standard in health care that is not efficiently/appropriately/consistently being done (4). For these reasons, QI focuses on translating existing knowledge into programs or practices to immediately improve the quality of services to individuals and populations within a local institution or setting (5). The risk of participation in QI is the same as the risk of receiving standard clinical care (6) since the standard of care remains the same for all patients.

In contrast, research projects use a systematic approach to discover something that is unknown. Research projects add new knowledge to what was previously unknown in literature through testing of a hypothesis or a scientific question (4). Research aims to generate knowledge with broad applications, often through controlled studies. The subjects may or may not benefit directly from the knowledge gained. Research studies aim to evaluate an innovation, study something new, or analyze a process not yet rigorously studied (6).

References

1. Baily MA, et al., Hastings Cent Rep, 2006.
2. Lynn J, et al., Ann Intern Med, 2007.
3. Centers for Medicare & Medicaid Services, Page Last Modified: 09/10/2024.
4. Jackson C, Research Quality Manager, Office of Research and Scholarship University of Maryland, Baltimore School of Nursing.
5. Columbia University Institutional Review Board Guidance for the Classification of Quality Improvement Activities Versus Research with human Subjects, 2023.
6. Newhouse et al., J Nurs Adm, 2006. Bibliography of relevant references.

Appendix

IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
- List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.

Assessment of Need for the Project

- Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.

Target Audience

- Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population

Project Design and Methods

- Describe the planned project and the way it addresses the established need.
- If your methods include educational activities, please describe succinctly the topic(s) and format of those activities.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.
- Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data.
- Quantify the amount of change expected from this project in terms of your target audience.
- Describe how the project outcomes will be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- The budget amount requested must be in EURO (EUR).
- While estimating your budget please keep the following items in mind:
    - General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
    - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
    - Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.

      It should be noted that grants awarded through ER&G cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please click here for details.

Required Documents

- Project Plan or Proposal